Entero Therapeutics (NASDAQ:ENTO) Raised to “Hold” at Wall Street Zen

Entero Therapeutics (NASDAQ:ENTO) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a report issued on Friday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Entero Therapeutics in a research note on Saturday, September 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Entero Therapeutics Stock Up 0.2%

Shares of Entero Therapeutics stock opened at $4.35 on Friday. Entero Therapeutics has a twelve month low of $0.97 and a twelve month high of $5.47. The firm’s 50-day moving average price is $2.77 and its 200 day moving average price is $1.83.

Entero Therapeutics (NASDAQ:ENTO) last announced its earnings results on Thursday, August 14th. The company reported ($0.42) EPS for the quarter.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.